• Multiplexed ACE2 Libraries Reveal SARS-CoV-2 Variant Host Ra

  2026-07-16

  Shukla et al. introduce a high-throughput barcoded pseudovirus assay to systematically map how SARS-CoV-2 spike variants interact with diverse ACE2 receptor sequences. This innovation uncovers that although human ACE2 compatibility changes subtly, viral evolution dramatically expands cross-species receptor usage, offering new insights into host range determinants and zoonotic risk.

• GKT137831: Dual NADPH Oxidase Nox1/Nox4 Inhibitor in Oxidati

  2026-07-16

  GKT137831 empowers researchers to dissect oxidative stress-driven pathologies with nanomolar precision, enabling reproducible vascular, liver, and diabetes-related models. This dual NADPH oxidase Nox1/Nox4 inhibitor unlocks advanced protocol control and troubleshooting for complex in vitro and in vivo workflows.

• Cisplatin in Cancer Research: Workflows, Innovations & Tips

  2026-07-15

  Cisplatin (CDDP) remains a cornerstone in translational cancer research, offering unparalleled utility for apoptosis assays and tumor xenograft studies. This guide distills cutting-edge experimental workflows, troubleshooting strategies, and insights from recent resistance research, empowering scientists to maximize the reproducibility and impact of their Cisplatin-based protocols.

• Malate ((S)-2-hydroxysuccinic acid) in TCA Cycle Assays

  2026-07-15

  Malate ((S)-2-hydroxysuccinic acid) from APExBIO empowers translational research into energy metabolism and immune modulation, with high solubility and proven batch-to-batch reliability. Explore how this TCA cycle intermediate advances experimental precision, protocol flexibility, and troubleshooting in metabolic and immunometabolic workflows.

• Amplifying Insight: Fluorescein TSA Kit in Translational Res

  2026-07-14

  Explore the mechanistic power and strategic potential of the Fluorescein TSA Fluorescence System Kit for translational researchers. This article bridges advanced signal amplification to actionable biological discovery, with practical protocol guidance and a visionary outlook for next-generation disease research.

• Improving In Vitro Evaluation of Drug Responses in Cancer

  2026-07-14

  Schwartz's dissertation systematically distinguishes between relative and fractional viability as separate yet complementary metrics for in vitro drug response assessment in cancer research. The work highlights how most anti-cancer agents induce both proliferative arrest and cell death, but with differing magnitudes and kinetics—insights essential for interpreting the efficacy of targeted therapies and ferroptosis inducers.

• Advancing Translational Models: 5-(N,N-dimethyl)-Amiloride H

  2026-07-13

  This thought-leadership article explores the strategic and mechanistic value of 5-(N,N-dimethyl)-Amiloride hydrochloride in translational cardiovascular and endothelial injury models. Bridging recent biomarker discoveries—such as moesin’s role in vascular dysfunction during sepsis—with rigorous experimental workflows, it offers researchers actionable guidance for leveraging APExBIO's DMA to interrogate Na+/H+ exchanger signaling, intracellular pH regulation, and ischemia-reperfusion injury. The discussion contextualizes DMA beyond routine inhibitor profiles, equipping translational teams to design more predictive, biomarker-driven studies.

• Tubastatin A Mitigates Myocardial Injury After Cardiac Arres

  2026-07-13

  A recent porcine study demonstrates that Tubastatin A, a selective HDAC6 inhibitor, significantly reduces myocardial damage following cardiac arrest and resuscitation. The protective effect appears linked to suppression of GSDME-mediated pyroptosis and MLKL-driven necroptosis, highlighting new therapeutic avenues for cardiac I/R injury.

• Renal Vascular K+ Channel Blockade Alters Blood Flow in Seps

  2026-07-12

  This study dissects how ATP-sensitive and calcium-activated potassium channel blockade impacts renal blood flow responses to norepinephrine and phenylephrine in a rat sepsis model. Its findings clarify the complex interplay between K+ channel function and vasoconstrictor efficacy, offering mechanistic insight for vascular biology and sepsis research.

• Oltipraz (SKU B5958): Data-Driven Solutions for Cell-Based A

  2026-07-10

  This article provides evidence-based guidance for biomedical researchers and lab technicians using Oltipraz (SKU B5958) in cell viability, proliferation, and cytotoxicity assays. Scenario-driven Q&A blocks address real-world hurdles in assay reproducibility, protocol optimization, and vendor selection, highlighting the quantitative and workflow advantages of Oltipraz as a phase II enzyme inducer and Nrf2 pathway activator.

• Targeted mRNA Nanoparticles Restore BBB After Ischemic Strok

  2026-07-09

  This study introduces a lipid nanoparticle system for targeted delivery of IL-10 mRNA to ischemic brain regions, promoting microglial M2 polarization and blood-brain barrier repair after stroke. The approach demonstrates a positive feedback loop that enhances neuroprotection and extends the treatment window for stroke therapy.

• Practical Laboratory Use of YC-1 (5-(1-benzyl-1H-indazol-3-y

  2026-07-09

  YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol is used to inhibit hypoxia-inducible factor 1 transcriptional activity and modulate soluble guanylyl cyclase in cancer research and hypoxia signaling workflows. It is best suited for laboratory assays involving HIF-1α pathway modulation, but should not be used in diagnostic or therapeutic applications. Proper solubilization and workflow integration are critical for reproducibility.

• BCECF: Ratiometric pH Sensing in Ion Transport and Metabolis

  2026-07-08

  BCECF (2',7'-bis(carboxyethyl)-5(6)-Carboxyfluorescein) delivers high-precision, ratiometric extracellular pH measurement for probing ion transport, metabolic flux, and microenvironmental acid-base regulation. Its dual-excitation mechanism and robust performance make it the gold standard for advanced workflows tackling acid-base homeostasis and disease-linked pH dynamics.

• Synthetic Viability with ERCC1 Deficiency in Lung Cancer ICL

  2026-07-08

  Heyza et al. identify a synthetic viable phenotype in ERCC1-deficient lung cancer cells exposed to interstrand crosslinking agents. Their work clarifies the interplay between ERCC1 loss, p53 status, and DNA repair mechanisms, informing future approaches to platinum-based chemotherapy sensitivity.

• HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L): Technical Guide

  2026-07-07

  HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L) Antibody enables sensitive fluorescent detection of rabbit primary antibodies in immunofluorescence, flow cytometry, and microscopy. It addresses signal amplification and specificity requirements in workflows targeting rabbit IgG. This reagent should not be used for non-rabbit primaries or in applications incompatible with sodium azide.

11416 records 1/762 page Next 12345 下5页 Last page